<- Go Home
enGene Therapeutics Inc.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Market Cap
$111.9M
Volume
422.9K
Cash and Equivalents
$36.6M
EBITDA
-$127.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$12.25
52 Week Low
N/A
Dividend
N/A
Price / Book Value
0.40
Price / Earnings
N/A
Price / Tangible Book Value
0.40
Enterprise Value
-$130.6M
Enterprise Value / EBITDA
N/A
Operating Income
-$127.7M
Return on Equity
46.07%
Return on Assets
-25.63
Cash and Short Term Investments
$275.9M
Debt
$33.5M
Equity
$281.5M
Revenue
N/A
Unlevered FCF
-$63.4M
Sector
Biotechnology
Category
N/A